THERAPEUTICS
Combined HRT increased CV events more than placebo but did not differ from oestrogen HRT after menopause
| The first 150 words of the full text of this article appear below. |
A H MacLennan
Dr A H MacLennan, University of Adelaide, Adelaide, South Australia, Australia; alastair.maclennan@adelaide.edu.au
STUDY DESIGN
randomised controlled trial (Womens International Study of long Duration Oestrogen after Menopause [WISDOM]).
concealed.*
blinded ({patients, healthcare providers}
, and outcome assessors).*
384 general practices in the UK, 91 in Australia, and 24 in New Zealand.
STUDY QUESTION
5692 women, 50–69 years of age (mean age 63 y), who were postmenopausal and achieved 80% compliance during a 12-week run-in period. Exclusion criteria included previous breast cancer; cancer other than basal or squamous cell skin cancer within the past 10 years; endometriosis or endometrial hyperplasia; venous thromboembolism (VTE); current gall stones; and
1 of the following within the past 6 months—myocardial infarction (MI), unstable angina, cerebrovascular accident, subarachnoid haemorrhage, transient ischaemic attack, or use of hormone replacement therapy (HRT) unless willing to discontinue before randomisation.
combined HRT (oral conjugated equine oestrogen, 0.625 mg daily, plus oral medroxyprogesterone acetate,
University of Toronto, Toronto, Ontario, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
